Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,034 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hematopoietic Stem Cell Transplantation (HSCT) Clear all
Completed Phase 2 Interventional

Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia

NCT00001144
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Graft vs Host Disease
Interventions
Modified bone marrow stem cell transplantation
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 16, 2026, 10:10 PM EDT
Not listed Phase 2 Interventional

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

NCT00003284
View directory record Official record
Conditions
Lung Cancer
Interventions
filgrastim, carboplatin, etoposide, ifosfamide, paclitaxel, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2014 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated No phase listed Observational

A Long-term Follow-up Study of Patients Who Received VOR33

NCT05309733
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
VOR33
Genetic
Lead sponsor
Vor Biopharma
Industry
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
La Jolla, California • Miami, Florida • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress

NCT02037568
View directory record Official record
Conditions
Hematopoietic/Lymphoid Cancer
Interventions
fPER
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 16, 2026, 10:10 PM EDT
Active, not recruiting Phase 1 Interventional

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

NCT05015426
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gamma Delta T-Cell Infusion
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 10:10 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers Results available

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

NCT03560752
View directory record Official record
Conditions
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Phase CML, BCR-ABL1 Positive, Cytomegalovirus Positive, Donor, Hematopoietic Cell Transplant Recipient, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional Results available

Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation

NCT03641378
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Palliative Care Intervention, Standard Transplant Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Not applicable Interventional

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

NCT00068523
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 16, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

NCT01962415
View directory record Official record
Conditions
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions
Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Drug
Lead sponsor
Paul Szabolcs
Other
Eligibility
2 Months to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

NCT01393717
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
brentuximab vedotin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
11 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Duarte, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 16, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional

Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

NCT04572815
View directory record Official record
Conditions
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
Interventions
Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration, Ustekinumab
Drug · Other · Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Duarte, California • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Crohn's Disease Stem Cell Transplantation

NCT00271947
View directory record Official record
Conditions
Crohn's Disease
Interventions
Autologous Stem Cell Transplantation
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

NCT01043640
View directory record Official record
Conditions
Mucopolysaccharidosis, Hurler Syndrome, Hunter Syndrome, Maroteaux-Lamy Syndrome, Sly Syndrome, Alpha Mannosidosis, Fucosidosis, Aspartylglucosaminuria, Adrenoleukodystrophy (ALD), Krabbe Disease, Metachromatic Leukodystrophy (MLD), Sphingolipidoses, Peroxisomal Disorders
Interventions
Campath-1H, Cyclophosphamide, Busulfan, Allogeneic stem cell transplantation, Cyclosporine A, Mycophenolate Mofetil
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013
View directory record Official record
Conditions
Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, donor lymphocytes, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, reduced-intensity transplant conditioning procedure, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 69 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Lewes, Delaware • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

NCT03149055
View directory record Official record
Conditions
Hematologic Malignancy, Myeloproliferative Disorder
Interventions
Isavuconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2Phase 3 Interventional

Extracorporeal Photopheresis for Acute Graft Versus Host Disease

NCT00179855
View directory record Official record
Conditions
Graft Versus Host Disease, Cancer, Stem Cell Transplantation
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Completed No phase listed Observational

Radiation Biodosimetry in Children Undergoing Total Body Irradiation

NCT01337648
View directory record Official record
Conditions
Total-body Irradiation, Hematopoietic Stem Cell Transplant
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Early Phase 1 Interventional

Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation

NCT03529825
View directory record Official record
Conditions
Microbial Colonization
Interventions
Rifaximin
Drug
Lead sponsor
Emory University
Other
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 16, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional Results available

Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies

NCT01678443
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
indium In 111 anti-CD45 monoclonal antibody BC8, yttrium Y 90 anti-CD45 monoclonal antibody BC8, peripheral blood stem cell transplantation
Biological · Radiation · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01842308
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carfilzomib, Laboratory Biomarker Analysis, Melphalan
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT02396134
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Hodgkin Lymphoma, Adult Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, HLA-A*0201 Positive Cells Present, Myelodysplastic Syndrome, Adult Lymphoblastic Lymphoma, Chronic Lymphocytic Leukemia, Myelofibrosis, Myeloproliferative Neoplasm
Interventions
CMVpp65-A*0201 peptide vaccine, Placebo, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • Atlanta, Georgia • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 16, 2026, 10:10 PM EDT
Withdrawn Phase 4 Interventional

Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients

NCT03963999
View directory record Official record
Conditions
Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Bone Marrow Transplant Complications, Stem Cell Transplant Complications
Interventions
Ultrasound Elastography, Contrast Enhanced Ultrasound (CEUS)
Diagnostic Test · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 16, 2026, 10:10 PM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing

NCT01416025
View directory record Official record
Conditions
Fungal Infection
Interventions
Prospective TDM Arm
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 100 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Oct 16, 2026, 10:10 PM EDT
Active, not recruiting Phase 2 Interventional

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT02861417
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Lymphoproliferative Disorder, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Pharmacological Study, Tacrolimus, Thiotepa
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 75 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 16, 2026, 10:10 PM EDT